We performed molecular identification and antifungal susceptibilities of pathogens and investigated clinical features of 43 culture-proven Fusarium keratitis cases from 2015–2020 in Taiwan. The pathogens were identified by sequencing of their internal transcribed spacer regions of ribosomal DNA and translation elongation factor 1α gene; their antifungal susceptibilities (to seven agents) were determined by broth microdilution method. We also collected clinical data to compare the drug susceptibilities and clinical features of Fusarium solani species complex (FSSC) isolates with those of other Fusarium species complexes (non-FSSC). The FSSC accounted for 76.7% pathogens, among which F. falciforme (32.6%) and F. keratoplasticum (27.9%) were the most common species. Among clinically used antifungal agents, amphotericin B registered the lowest minimal inhibitory concentration (MIC), and the new azoles efinaconazole, lanoconazole and luliconazole, demonstrated even lower MICs against Fusarium species. The MICs of natamycin, voriconazole, chlorhexidine, lanoconazole, and luliconazole were higher for the FSSC than the non-FSSC, but no significant differences were noted in clinical outcomes, including corneal perforation and final visual acuity. In Taiwan, the FSSC was the most common complex in Fusarium keratitis; its MICs for five tested antifungal agents were higher than those of non-FSSC, but the clinical outcomes did not differ significantly.
Objectives: Scedosporium and Lomentospora species are intrinsically resistant molds increasingly implicated in invasive infections with poor outcomes. Olorofim, a novel orotomide antifungal, has demonstrated potent activity against various molds. This study evaluated the antifungal susceptibility of clinical and environmental isolates, focusing on olorofim, and examined these data in a phylogenetic context. Methods: A total of 216 isolates ( Scedosporium spp., n=205; L. prolificans , n=11) were collected from clinical and environmental sources across Taiwan. Species identification was confirmed by sequencing of the ITS and β-tubulin regions, followed by maximum-likelihood phylogenetic analysis. Antifungal susceptibility was determined using CLSI M38-A3 method. Cross-resistance was evaluated using correlation analyses. Phylogenetic signal, Mantel tests, and variance partitioning were applied to assess the evolutionary structuring of minimum inhibitory concentrations (MICs). Results: Scedosporium apiospermum (46.3%) and S. boydii (15.7%) were the predominant species, exhibiting comparable triazole susceptibility profiles (MIC 90 : voriconazole 1-2 mg/L, posaconazole 4 mg/L, and isavuconazole 8 mg/L). L. prolificans displayed pan-resistance to all agents except olorofim. Among triazoles, voriconazole yielded the lowest MICs for most Scedosporium isolates. Olorofim exhibited the lowest MICs across Scedosporium spp. and L. prolificans (all MIC 90 ≤0.12 mg/L). Rare taxa ( S. marinum , S. haikouense , S. multisporum , S. minutisporum , S. sp. nov.1) were also identified, exhibiting variable triazole MICs but consistently low olorofim MICs. The association between antifungal susceptibility and species relatedness varied by drug: moderate for posaconazole, amphotericin B, and voriconazole; intermediate for olorofim; weak for isavuconazole; and absent for itraconazole. Most MIC variability (72.5–89.2%) occurred within rather than between species. Conclusions: Antifungal susceptibility among Scedosporium spp. and L . prolificans was drug dependent. Olorofim demonstrated consistently low MICs across species, whereas amphotericin B and triazoles showed variable, species-specific activity. These findings highlight olorofim as a promising therapeutic option and emphasize the need for target gene-based investigations to elucidate the evolutionary basis of antifungal resistance.